Angiotensin receptor blocker neprilysin inhibitors

查看全文 作　　者：Daisuke [1]Usuda;Toshihiro [2]Higashikawa;Yuta [1]Hotchi;Kenki [1]Usami;Shintaro [1]Shimozawa;Shungo [1]Tokunaga;Ippei [1]Osugi;Risa [1]Katou;Sakurako [1]Ito;Toshihiko [1]Yoshizawa;Suguru [1]Asako;Kentaro [1]Mishima;Akihiko [1]Kondo;Keiko [1]Mizuno;Hiroki [1]Takami;Takayuki [1]Komatsu;Jiro [1]Oba;Tomohisa [1]Nomura;Manabu [1]Sugita

机构地区：[1]Emergency and Critical Care Medicine,Juntendo University Nerima Hospital,Nerima-ku 177-8521,Tokyo,Japan;[2]Geriatric Medicine,Kanazawa Medical University Himi Municipal Hospital,Himi-shi 935-8531,Toyama,Japan

出　　处：《World Journal of Cardiology》索引2021年第13卷第8期,共15页

摘　　要：Heart failure(HF)is a clinical syndrome that results from a structural or functional cardiac disorder that reduces the ability of the ventricle of the heart to fill with,or eject,blood.It is a multifaceted clinical condition that affects up to 2%of the population in the developed world,and is linked to significant morbidity and mortality;it is therefore considered a major concern for public health.Regarding the mechanism of HF,three neurohumoral factors-the reninangiotensin-aldosterone system,the sympathetic nervous system,and natriuretic peptides—are related to the pathology of chronic HF(CHF),and the targets of treatment.Angiotensin receptor blocker and neprilysin inhibitor(angiotensinreceptor neprilysin inhibitor),namely sacubitril/valsartan(SAC/VAL),has been introduced as a treatment for CHF.SAC/VAL is an efficacious,safe,and costeffective therapy that improves quality of life and longevity in patients with HF with reduced ejection fraction(HFrEF),and reduces hospital admissions.An inhospital initiation strategy offers a potential new avenue to improve the clinical uptake of SAC/VAL.In the last five years,SAC/VAL has been established as a cornerstone component of comprehensive disease-modifying medical therapy in the management of chronic HFrEF.On the other hand,further work,with carefully designed and controlled preclinical studies,is necessary for understanding the molecular mechanisms,effects,and confirmation of issues such as long-term safety in both human and animal models. 关键词：Angiotensin receptor blocker and neprilysin inhibitor Chronic heart failure Renin-angiotensin-aldosterone-system Sympathetic nervous system Natriuretic peptide Sacubitril/valsartan

相关文献

参考文献（57）
引证文献（3）
耦合文献（0）

参考文献(57)

引证文献(3)

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

Angiotensin receptor blocker neprilysin inhibitors

参考文献(57)

引证文献(3)

用户提示